---
layout: post
title:  "59 aptamer"
date:   2024-05-05 00:00:00
author: Ke Chen, Yangyi Ren
categories: Aptamer
---
<!--p style="font-size: 24px"><strong>Keywords: </strong> <br/></p>
<font ><strong>small molecule, Synthetic, dyes, PubChem CID 25863</strong></font >
<br /-->

<html>
<head>
  <title>横向排列的点击按钮</title>
  <style>
    /* 按钮容器样式 */
    .button-container {
      display: flex;
      justify-content: left;
      align-items: center;
      height: 50px;
    }
    /* 按钮样式 */
    .button {
      display: block;
      padding: 10px;
      font-size:24px;
      margin-right: 10px;
      text-align: center;
      background-color: #ffffff;
      color: #520049;
      text-decoration: none;
      border: 1px solid #520049;
      border-radius: 5px;
    }
    /* 鼠标悬停样式 */
    .button:hover {
      background-color: #c9c5c5;
      cursor: pointer;
    }
  </style>
</head>
<!--body>
  <p style="font-size: 16px">Click the buttons to navigate to different sections:</p>
  <div class="button-container">
    <a class="button" style="color:#520049" href="#description">Description</a>
    <a class="button" style="color:#520049" href="#SELEX">SELEX</a>
    <a class="button" style="color:#520049" href="#structure">Structure</a>
    <a class="button" style="color:#520049" href="#ligand-recognition">Ligand recognition
    <a class="button" style="color:#520049" href="#references">References</a>
   </a>
  </div>
</body-->
</html>

<html lang="zh-cn">
<head>
<meta charset="utf-8"> 
<style>
    .header_box {
     display: block;
      padding: 10px;
      font-size:24px;
      margin-right: 10px;
      text-align: center;
      background-color: #efefef;
      color: #000000;
      text-decoration: none;
      border: 1px solid #c9c5c5;
      border-radius: 5px;
      width:225px;
	    height:50px;
  }
  .header_boxx1 {
    display: block;
      padding: 10px;
      font-size:24px;
      margin-right: 10px;
      text-align: left;
      background-color: #ffffff;
      text-decoration: none;
      border-radius: 1px;
      width:115px;
	    height:50px;
      border-width: 1px 1px 2px 1px;
      border-style: solid solid solid solid;
      border-color:#ffffff #ffffff #ccc #ffffff;
  }
  .header_boxx2 {
    display: block;
      padding: 10px;
      font-size:24px;
      margin-right: 10px;
      text-align: left;
      background-color: #ffffff;
      text-decoration: none;
      border-radius: 1px;
      width:140px;
	    height:50px;
      border-width: 1px 1px 2px 1px;
      border-style: solid solid solid solid;
      border-color:#ffffff #ffffff #ccc #ffffff;
  }
  .header_boxx3 {
    display: block;
      padding: 10px;
      font-size:24px;
      margin-right: 10px;
      text-align: left;
      background-color: #ffffff;
      text-decoration: none;
      border-radius: 1px;
      width:85px;
	    height:50px;
      border-width: 1px 1px 2px 1px;
      border-style: solid solid solid solid;
      border-color:#ffffff #ffffff #ccc #ffffff;
  }
  .header_boxx4 {
    display: block;
      padding: 10px;
      font-size:24px;
      margin-right: 10px;
      text-align: left;
      background-color: #ffffff;
      text-decoration: none;
      border-radius: 1px;
      width:120px;
	    height:50px;
      border-width: 1px 1px 2px 1px;
      border-style: solid solid solid solid;
      border-color:#ffffff #ffffff #ccc #ffffff;
  }
  .header_boxx5 {
    display: block;
      padding: 10px;
      font-size:24px;
      margin-right: 10px;
      text-align: left;
      background-color: #ffffff;
      text-decoration: none;
      border-radius: 1px;
      width:215px;
	    height:50px;
      border-width: 1px 1px 2px 1px;
      border-style: solid solid solid solid;
      border-color:#ffffff #ffffff #ccc #ffffff;
  }
  .header_boxx6 {
    display: block;
      padding: 10px;
      font-size:24px;
      margin-right: 10px;
      text-align: left;
      background-color: #ffffff;
      text-decoration: none;
      border-radius: 1px;
      width:135px;
	    height:50px;
      border-width: 1px 1px 2px 1px;
      border-style: solid solid solid solid;
      border-color:#ffffff #ffffff #ccc #ffffff;
  }
  .blowheader_box{
    display: block;
      padding: 10px;
      font-size:18px;
      margin-right: 10px;
      text-align: center;
      background-color: #efefef;
      color: #000000;
      text-decoration: none;
      border: 1px solid #ffffff;
      border-radius: 5px;
      width:170px;
	    height:40px;
  }
  .box_style{
    background: #ffffff;
  }
  blockquote {
  margin: 0 0 0px;
  }
</style>
</head>
<br>
<br>


<font ><p class="header_boxx2" id="description">Description</p></font>
<font >In 1993, Lori Giver and colleagues used the SELEX method to isolate the aptamer with high affinity for the HIV-1 Rev protein. It can competitively bind Rev protein with RRE, thereby preventing RRE from interacting with Rev protein. Refer to the RBA-14 aptamer page for specific aptamer<sup>[<a href="#ref1" style="color:#520049">1</a>]</sup>.<br></font>
<br>
<br>


<p class="header_boxx3" id="SELEX">SELEX</p>
<p>In 1993, Lori Giver et al. constructed a pool of random sequences. After in vitro selecting in the pool, selected RNAs were amplified via reverse transcription, PCR amplification, in vitro T7 transcription, and allowed to again compete for binding to Rev. Some aptamers with high affinity were selected after three selection cycles<sup>[<a href="#ref1" style="color:#520049">1</a>]</sup>.<br>
Detailed information are accessible on <a href="{{ site.url }}{{ site.baseurl }}/SELEX" target="_blank" style="color:#520049"><b><i>SELEX</i></b></a> page.</p>
<br>
<br>


<p class="header_boxx4" id="Structure">Structure</p>
<font>59 was the aptamer sequence mainly studied in the article, which had a high affinity with HIV-1 Rev protein. The 2D structure of the figure is based on the prediction results of the RNA fold website by ribodraw tool to draw<sup>[<a href="#ref1" style="color:#520049">1</a>]</sup>.<br></font>
<font><p>5'-AUUCUGGCUUCGUACGCAAGUAUGAUGAUACAG-3'</p></font>
<!--b>2D representation</b-->
        
<!--font><p>Szostak et al. obtained 17 different sequences through SELEX, and designed a 40nt sequence after comparing the information of 17 sequences. The aptamer of the 40nt is a sequence of analytic structures, and the following diagram shows its secondary structure.
Through SELEX, 17 different sequences were obtained, and after comparing 17 sequence information, a 40nt sequence was designed
 <sup>[<a href="#ref2" style="color:#520049">2</a>]</sup>.</p></font-->
<img src="/images/2D/59_aptamer_2D.svg" alt="drawing" style="width:800px;display:block;margin:0 auto;border-radius:0;" class="img-responsive">
<div style="display: flex; justify-content: center;">   
</div>
 <br>
                     
<!--b>3D visualisation</b><br>               
<font >ATP aptamer complex was generated from PDB ID:  at 3.05 Å . Additional available structures that have been solved and detailed information are accessible on <i>Structures</i> page <sup>[<a href="#ref3" style="color:#520049" >3</a>]</sup>.</font>
  <table class="table table-bordered" style="table-layout:fixed;width:1000px;margin-left:auto;margin-right:auto;"><tr>
  <td style="text-align:center;padding-bottom: 0px;padding-left: 0px;padding-top: 0px;padding-right: 0px">
  <img src="/images/3D/AMP-3D.svg" alt="drawing" style="width:500px;margin-top: 0px;margin-bottom: 0px;" >
  </td>
  <td style="text-align:center;padding-bottom: 0px;padding-right: 0px;padding-top: 0px;padding-right: 0px">
  <img src="/images/3D/AMP-3D-bp.svg" alt="drawing" style="width:500px;margin-top: 0px;margin-bottom: 0px;" >
  </td>
  </tr>
  </table-->
  <br>

<font ><p class="header_boxx5" id="ligand-information">Ligand information</p></font>  
  

<p class="blowheader_box">SELEX ligand</p>
<font>REV is a viral anti-repression trans-activator protein, which appears to act post-transcriptionally to relieve negative repression of GAG and ENV production. It is a phosphoprotein whose state of phosphorylation is mediated by a specific serine kinase activity present in the nucleus. REV accumulates in the nucleoli.-----from Pfam</font>
<br>
<table class="table table-bordered" style="table-layout:fixed;width:1000px;margin-left:auto;margin-right:auto;" >
  <thead>
      <tr>
        <th onclick="sortTable(0)">Name</th>
        <th onclick="sortTable(1)">Uniprot ID</th>
        <th onclick="sortTable(2)">Pfam</th>
        <th onclick="sortTable(3)">MW</th>
        <th onclick="sortTable(4)">Amino acids sequences</th>
        <th onclick="sortTable(5)">PDB</th>
        <th onclick="sortTable(6)">Gene ID</th>
      </tr>
  </thead>
    <tbody>
      <tr>
        <td name="td0">HIV-1 Rev protein</td>
        <td name="td1"><a href="https://www.uniprot.org/uniprotkb/P04325/entry#sequences" target="_blank" style="color:#520049"><b>P04325</b></a></td>
        <td name="td2"><a href="https://www.ebi.ac.uk/interpro/entry/pfam/PF00424/" target="_blank" style="color:#520049"><b>PF00424</b></a></td>
        <td name="td3">2.4 kDa</td>
        <td name="td4">TRQARRNRARRWRARQR(residue 34-50)</td>
        <td name="td5"><a href="https://www.rcsb.org/structure/1RPV" target="_blank" style="color:#520049"><b>1RPV</b></a></td>
        <td name="td6"><a href="https://www.ncbi.nlm.nih.gov/protein/AAA45000.1" target="_blank" style="color:#520049"><b>AAA45000.1</b></a></td>
      </tr>
	  </tbody>
  </table>
<font>Some isolated sequences bind to the affinity of the protein.</font>
<br>
<table class="table table-bordered" style="table-layout:fixed;width:1000px;margin-left:auto;margin-right:auto;" >
  <thead>
      <tr>
        <th onclick="sortTable(0)">Name</th>
        <th onclick="sortTable(1)">Sequence</th>
        <th onclick="sortTable(2)">Ligand</th>
        <th onclick="sortTable(3)">Affinity</th>
      </tr>
  </thead>
    <tbody>
      <tr>
        <td name="td0">sequence 59</td>
        <td name="td1">5'-AUUCUGGCUUCGUACGCAAGUAUGAUGAUACAG-3'</td>
        <td name="td2">HIV-1 Rev protein</td>
        <td name="td3">0.2*</td>
      </tr>
	  </tbody>
     <tbody>
      <tr>
        <td name="td0">sequence 72</td>
        <td name="td1">5'-AUUCUGUAUGAGAGUAGCAAGUACCGGACUCUACAG-3'</td>
        <td name="td2">HIV-1 Rev protein</td>
        <td name="td3">0.3*</td>
      </tr>
	  </tbody>
      <tbody>
      <tr>
        <td name="td0">sequence 50</td>
        <td name="td1">5'-AUUCUGGUCUCGUACGCAAGUACUGAGAAACGACAG-3'</td>
        <td name="td2">HIV-1 Rev protein</td>
        <td name="td3">0.4*</td>
      </tr>
	  </tbody>
  </table>
<div style="display: flex; justify-content: center;"></div>
<img src="/images/SELEX_ligand/59_aptamer_SELEX_ligand.svg" alt="drawing" style="width:800px;display:block;margin:0 auto;border-radius:0;" class="img-responsive">
<div style="display: flex; justify-content: center;"></div>
<br>
<br>



                 
<p class="header_boxx6" id="references">References</p>
                
<a id="ref1"></a><font><strong>[1] Selective optimization of the Rev-binding element of HIV-1.</strong></font><br />
Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/7505429/" target="_blank" style="color:#520049" >Nucleic acids research, 21(23), 5509–5516. (1993)</a>
<br/>

<a id="ref2"></a><font><strong>[2] Selection and design of high-affinity RNA ligands for HIV-1 Rev.</strong></font><br />
Giver, L., Bartel, D. P., Zapp, M. L., Green, M. R., & Ellington, A. D.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/7506689/" target="_blank" style="color:#520049" >Gene, 137(1), 19–24. (1993)</a>
<br/>

<a id="ref3"></a><font><strong>[3] A three-dimensional model of the Rev-binding element of HIV-1 derived from analyses of aptamers.</strong></font><br />
Leclerc, F., Cedergren, R., & Ellington, A. D.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/7664035/" target="_blank" style="color:#520049" >Nature structural biology, 1(5), 293–300. (1994)</a>
<br/>

<a id="ref4"></a><font><strong>[4] RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo.</strong></font><br />
Symensma, T. L., Giver, L., Zapp, M., Takle, G. B., & Ellington, A. D.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/8523524/" target="_blank" style="color:#520049" >Journal of virology, 70(1), 179–187. (1996)</a>
<br/>

<a id="ref5"></a><font><strong>[5] Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs.</strong></font><br />
Konopka, K., Düzgüneş, N., Rossi, J., & Lee, N. S.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/9713975/" target="_blank" style="color:#520049" >Journal of drug targeting, 5(4), 247–259. (1998)</a>
<br/>

<a id="ref6"></a><font><strong>[6] Retention of conformational flexibility in HIV-1 Rev-RNA complexes.</strong></font><br />
Wilkinson, T. A., Zhu, L., Hu, W., & Chen, Y. <br />
<a href="https://pubmed.ncbi.nlm.nih.gov/15610009/" target="_blank" style="color:#520049" >Biochemistry, 43(51), 16153–16160. (2004)</a>
<br/>

<a id="ref7"></a><font><strong>[7] Structure of an RNA Aptamer that Can Inhibit HIV-1 by Blocking Rev-Cognate RNA (RRE) Binding and Rev-Rev Association.</strong></font><br />
Dearborn, A. D., Eren, E., Watts, N. R., Palmer, I. W., Kaufman, J. D., Steven, A. C., & Wingfield, P. T.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/30017564/" target="_blank" style="color:#520049" >Structure (London, England : 1993), 26(9), 1187–1195.e4. (2018)</a>
<br/>
                       